Last reviewed · How we verify
Zr89-trastuzumab
At a glance
| Generic name | Zr89-trastuzumab |
|---|---|
| Also known as | HER2 ImmunoPET/CT, HER2 receptor imaging, Breast cancer molecular imaging |
| Sponsor | Jules Bordet Institute |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1 (PHASE2)
- Pilot Imaging Study With 89Zr-Trastuzumab in HER2-positive Metastatic Breast Cancer Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zr89-trastuzumab CI brief — competitive landscape report
- Zr89-trastuzumab updates RSS · CI watch RSS
- Jules Bordet Institute portfolio CI